The efficacy and tolerance of parenterally administered piperacillin were evaluated in 50 adult patients hospitalized with systemic and urinary tract infections. Dosage for 46 patients was 4 to 12 g daily and for 4 patients, 16 to 24 g daily; in each case divided doses were given every 4 to 6 h. The duration of treatment for most patients was 5 to 10 days. Of the 50 patients, 45 (90%) were considered cured, and 57 (89o) of the 64 pathogens isolated were eradicated by piperacillin treatment. Side effects, reported by 12 patients, were mild to moderate in degree and consisted of vein irritation, thrombophlebitis, pain at the injection site, and diarrhea. Piperacillin appears to be a highly effective antibiotic for treating infections caused by susceptible gram-positive and gram-negative microorganisms.
Piperacillin, a new semisynthetic penicillin with a broad spectrum of activity against both gram-positive and gram-negative pathogens (2) (3) (4) (5) (6) (7) (8) (9) (10) , is currently undergoing clinical evaluations for efficacy and tolerability in a number of institutions. The present report summarizes the current results of one such investigation.
MATERIALS AND METHODS
A total of 62 adult, hospitalized patients (38 men and 24 women, 18 to 85 years of age) with lower respiratory tract infections, urinary tract infections, skin infections, and bacteremias suspected to be caused by piperacillin-susceptible bacteria were admitted to the study after giving their consent and after ascertaining that they were not allergic to penicillins. Pregnancy or the need for other concomitant systemic antibacterial agents precluded entry into the trial. About threefourths of the patients had significant underlying conditions, the most numerous of which were hypertension, chronic pulmonary disease, diabetes mellitus, anemia, and alcoholism. Other, less common conditions included cancer and drug abuse.
Appropriate culture specimens were obtained before beginning piperacillin treatment. The diagnosis of pneumonia was made by noting the presence of the pathogen in a Gram-stained smear and in a subsequent sputum culture, in addition to an appropriate clinical history and consistent X-ray findings. The pneumococcus was considered to be the pathogen if more than 50 colonies of this bacterium were present on the culture plate. The diagnosis of urinary tract infection was based on clinical findings and on a clean voided urine culture that contained 100,000 or more bacteria per ml. 
RESULTS
The efficacy of piperacillin therapy could not be evaluated in 12 of the 62 patients. Seven were excluded because of negative pretreatment cultures. One patient died on day 2 of the treatment course. Treatment of one was interrupted on day 4 of treatment because of acute renal failure. Treatment of two others was changed on days 13 and 20, respectively, when it was learned that pretreatment isolates were resistant to piperacillin. The 12th patient was given concomitant antimicrobial medication with an overlapping spectrum of activity.
In the 50 patients for whom efficacy could be judged, there were 56 infections (6 patients had multiple infections). These included 39 lower respiratory tract infections, 10 urinary tract infections, 6 bacterial septicemias, and 1 cellulitis. Of the 56 infections, 48 were acute, 4 were chronic, and 4 were recurrent.
Response. Eighty-nine percent (50 of 56) of the infections in 45 of 50 patients responded to piperacillin (Table 1 ). All patients with pneumococcal pneumonia and pneumonia caused by Haemophilus influenzae were cured. Two patients, one with staphylococcal pneumonia and one with Klebsiella sp. pneumonia, also responded with complete eradication of the bacteria.
Pseudomonas sp. pneumonias in two patients who were extremely ill with infections were complicated by underlying medical conditions that had poor, ultimately fatal, prognoses. In the first patient, Pseudomonas sp. and Klebsiella sp. pneumonia and lung abscess were not cured despite 3.5 g of piperacillin every 6 h for 9 days. Underlying conditions included chronic obstructive pulmonary disease, malignant lung neoplasm, syndrome of inappropriate antidiuretic hormone secretion, and impaired immune response. This patient died with an overwhelming infection on the 9th treatment day. The second patient, who had lung cancer and emphysema, was admitted with pneumonia caused by Pseudomonas aeruginosa. Although there was some clinical improvement and reduction in the number of pseudomonads on cultures after 16 g of piperacillin per day for 16 days, the final outcome was unsatisfactory. The patient was switched to another antibacterial agent but died 4 days later of metastatic lung cancer with pneumonia, empyema, and sepsis.
All 10 patients with urinary tract infections had negative urine cultures 7 days posttreatment and were classified as clinically cured. Of these, one bacteremic patient, a woman aged 39 years, received relatively low doses of piperacillin i.m.
(60 mg kg-' day-1) throughout her 10-day treatment period and responded very well within 4 days. Bacteriological relapses occurred in two patients when the infective pathogen, Escherichia coli, reappeared 11 and 18 days, respectively, after piperacillin treatment ended.
Left-sided Pseudomonas sp. endocarditis in a 30-year-old male drug addict responded initially to piperacillin, but increasing congestive heart failure developed from aortic valve insufficiency after 1 week of treatment, and the patient died on the 16th treatment day from complications during an invasive diagnostic procedure. At autopsy, Pseudomonas sp. was cultured from both aortic and mitral valve vegetations. The lack of response could be at least partially due to the need for surgical correction, which was not possible in this case.
Sixty-four pathogens were isolated from pretreatment cultures in the 50 patients. The MICs are shown in Table 1 . All pathogens were susceptible to piperacillin; the MIC was less than 32 ,ug/ml for each bacterium isolated. Seven of the isolates (three P. aeruginosa, three Klebsiella spp., and one Citrobacter strain), from six patients, were carbenicillin resistant, but had the following piperacillin MICs: P. aeruginosa, 12.5, 15.12, and 31.25 ,ug/ml; Klebsiella pneumoniae, 3.9 and 25 ,ug/ml; Klebsiella spp., 6.25 ,ug/ml; and Citrobacter sp., 3.12 ,ug/ml. Treatment of these infections resulted in four cures and two failures (two with P. aeruginosa and one with K. pneumoniae). At the end of treatment, 57 pathogens were eradicated and 6 persisted; one post-treatment culture was not done. All 31 isolates of pneumococci and H. influenzae were eradicated. Similarly, responses were obtained in all 10 urinary tract infections caused by 11 piperacillin-susceptible bacteria (E. coli, nine; Citrobacter sp., one; Enterobacter cloacae, one). Only two patients showed evidence of relapse.
P. aeruginosa persisted in the pleural fluid and urine and in the blood of two patients with pneumonia and endocarditis, respectively.
In eight patients, two bacteria were responsible for causing infections (Streptococcus pneumoniae and H. influenzae, four patients; S. pneumoniae and P. aeruginosa, one patient; P. aeruginosa and Klebsiella sp., one patient; H. influenzae and Klebsiella sp., one patient; and E. coli and E. cloacae, one patient). All of the patients responded, with the exception of the patient with pneumonia and lung abscess, in whom P. aeruginosa and Klebsiella sp. persisted despite 9 days of piperacillin treatment.
Adverse effects. Adverse reactions occurred in 12 of the 62 patients who were treated. Loose stools in one patient, dizziness in one patient, and diarrhea, which developed in three patients 
DISCUSSION
The need for a wide-spectrum antibiotic with increased activity against gram-negative bacteria (in addition to gram-positive activity) and with less toxicity than some presently available compounds led to the development of piperacillin sodium. In vitro studies have shown the effectiveness of piperacillin against many pathogens including P. aeruginosa, E. coli, Klebsiella sp., other members of Enterobacteriaceae, and Bacteroides spp. (2, 6, 7, 9) . The results of the present study generally agree with these reports. P. aeruginosa strains with carbenicillin MICs of 31.0 to 1,000 ,ug/ml were inhibited by 3.9 to 31.25 pg of piperacillin per ml. Similarly, for the E. coli isolates, the carbenicillin MIC range was 3.1 to 25.0 ,ug/ml compared with 0.78 to 3.1 pxg of piperacillin per ml. Gram-positive activity also was evident; all strains of Streptococcus pneumoniae and H. influenzae were inhibited by 0.02 to 0.04 ,ug of piperacillin per ml.
This 
